Prohibitin overexpression improves myocardial function in diabetic cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Metabolic Diseases
• Molecular Medicine

Background:

• Prohibitin (PHB) is a conserved protein involved in cell proliferation, apoptosis, and mitochondrial function.
• The role of PHB in diabetic cardiomyopathy (DCM) remains largely unknown.
• Diabetic cardiomyopathy is characterized by insulin resistance, cardiac dysfunction, fibrosis, and apoptosis.

Purpose of the Study:

• To investigate the role of Prohibitin (PHB) in the pathogenesis of type 2 diabetic cardiomyopathy (DCM).
• To explore the therapeutic potential of PHB overexpression in ameliorating DCM.
• To elucidate the molecular mechanisms underlying PHB's effects in DCM.

Main Methods:

• A type 2 diabetic rat model was established using a high-fat diet and streptozotocin.
• PHB overexpression was induced in vivo via lentiviral gene delivery.
• Cardiac function was assessed using metabolic tests, echocardiography, and histopathology.
• In vitro studies utilized cardiofibroblasts and H9c2 cardiomyoblasts under high glucose conditions.

Main Results:

• PHB overexpression significantly ameliorated DCM symptoms, including insulin resistance, left ventricular dysfunction, fibrosis, and apoptosis.
• In cardiofibroblasts, PHB overexpression reduced collagen expression, matrix metalloproteinase activity, and proliferation.
• In H9c2 cardiomyoblasts, PHB overexpression inhibited high glucose-induced apoptosis.
• PHB overexpression modulated key signaling pathways, decreasing ERK1/2 phosphorylation and restoring Akt phosphorylation.

Conclusions:

• Prohibitin (PHB) plays a protective role in diabetic cardiomyopathy.
• PHB overexpression demonstrates therapeutic potential for treating DCM.
• PHB influences key cellular processes like fibrosis, apoptosis, and signaling pathways in DCM.